U.S. Luxury Stock News

NYSE:LAZ
NYSE:LAZCapital Markets

Lazard Taps Insider Tracy Farr As CFO To Shape 2030 Plan

Lazard (NYSE:LAZ) has appointed Tracy Farr as its new Chief Financial Officer. The leadership change is intended to support the firm's long term growth and operational efficiency plans. Farr brings extensive internal experience at Lazard to the CFO role. Lazard, traded on the NYSE under the ticker NYSE:LAZ, recently closed at $53.72. The stock has seen a 4.6% return over the past week and 10.6% over the past month, with a 62.1% return over five years. In that context, a CFO transition can...
NYSE:CAT
NYSE:CATMachinery

Caterpillar (CAT) Margin Compression Challenges Bullish Earnings Growth Narratives

Caterpillar (CAT) just turned in its FY 2025 scorecard with fourth quarter revenue of US$19.1b and basic EPS of US$5.15, alongside net income of US$2.4b. Over recent quarters, the company has seen revenue move from US$16.0b in Q3 2024 to US$17.6b in Q3 2025 and then US$19.1b in Q4 2025. Basic EPS shifted from US$5.09 to US$4.91 and then US$5.15 over the same stretch, setting up a results season where investors are weighing solid top line scale against a backdrop of compressed net margins and...
NYSEAM:CET
NYSEAM:CETCapital Markets

Central Securities (CET) Valuation After Net Asset Growth And All Time High Share Price

Central Securities (CET) has been in focus after reporting 9.3% year over year growth in net assets and higher net assets per share, alongside its stock touching an all time high of US$52.46. See our latest analysis for Central Securities. The latest share price of US$52.10 sits just below its recent all time high, and the 1 year total shareholder return of 15.44% and 5 year total shareholder return of 106.06% point to momentum that has built over time rather than fading quickly. If Central...
NasdaqGS:OLMA
NasdaqGS:OLMABiotechs

Is It Too Late To Consider Olema Pharmaceuticals (OLMA) After Its 320% One-Year Surge?

If you are wondering whether Olema Pharmaceuticals is still priced attractively after its recent run, this article walks through the numbers in a clear, valuation focused way. The stock recently closed at US$25.72, with returns of 1.9% over 7 days, 2.9% over 30 days, 1.7% year to date and 320.9% over the past year, while the 3 year return sits at 465.3% and the 5 year return at a 45.7% decline. Recent attention on Olema has centered on its position in the pharmaceuticals and biotech space...
NYSE:WT
NYSE:WTCapital Markets

WisdomTree (WT) Earnings Growth And 20.7% Margin Test Valuation‑Skeptic Narratives

WisdomTree (WT) just posted its FY 2025 third quarter numbers, with total revenue of US$125.6 million and basic EPS of US$0.14, setting the tone with US$19.0 million in net income excluding extraordinary items. The company has seen quarterly revenue move from US$108.1 million in Q1 FY 2025 to US$112.6 million in Q2 and US$125.6 million in Q3. Basic EPS shifted from US$0.17 in Q1 and Q2 to US$0.14 in Q3, all against a trailing twelve month backdrop of US$457.0 million in revenue and EPS of...
NYSE:GLP
NYSE:GLPOil and Gas

Is It Time To Reassess Global Partners (GLP) After Big Five Year Share Gains?

If you are wondering whether Global Partners' share price still offers value after past gains and recent swings, starting with a clear look at its current valuation can help frame your next move. Over shorter periods the stock has had mixed returns, with 6.7% over the past week, 12.8% over the past month, 11.7% year to date, a 7.3% decline over the past year and a very large gain of about 2.4x over five years. Recent price moves sit against a backdrop of ongoing interest in energy...